UBS Asset Management Americas Inc. Sells 19,662 Shares of Omeros Corporation (OMER)

UBS Asset Management Americas Inc. cut its stake in Omeros Corporation (NASDAQ:OMER) by 40.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 28,654 shares of the biopharmaceutical company’s stock after selling 19,662 shares during the period. UBS Asset Management Americas Inc. owned about 0.07% of Omeros Corporation worth $284,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the company. State Street Corp increased its stake in Omeros Corporation by 4.6% in the fourth quarter. State Street Corp now owns 943,121 shares of the biopharmaceutical company’s stock valued at $9,362,000 after buying an additional 41,284 shares during the period. Ingalls & Snyder LLC increased its stake in Omeros Corporation by 15.2% in the third quarter. Ingalls & Snyder LLC now owns 5,085,949 shares of the biopharmaceutical company’s stock valued at $56,759,000 after buying an additional 671,370 shares during the period. Norges Bank bought a new stake in Omeros Corporation during the fourth quarter valued at approximately $744,000. First Allied Advisory Services Inc. bought a new stake in Omeros Corporation during the fourth quarter valued at approximately $108,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in Omeros Corporation during the fourth quarter valued at approximately $263,000. 45.44% of the stock is currently owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Omeros Corporation (NASDAQ:OMER)

Shares of Omeros Corporation (NASDAQ:OMER) traded up 7.22% during trading on Friday, reaching $23.75. The company had a trading volume of 4,155,759 shares. The stock’s 50-day moving average price is $16.37 and its 200-day moving average price is $12.93. The company’s market capitalization is $1.04 billion. Omeros Corporation has a 52 week low of $7.20 and a 52 week high of $25.10.

Omeros Corporation (NASDAQ:OMER) last issued its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.01. The business had revenue of $12.26 million for the quarter, compared to analysts’ expectations of $13.32 million. During the same period last year, the business earned ($0.54) earnings per share. The company’s revenue for the quarter was up 65.2% on a year-over-year basis. On average, equities analysts expect that Omeros Corporation will post ($1.32) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “UBS Asset Management Americas Inc. Sells 19,662 Shares of Omeros Corporation (OMER)” was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.chaffeybreeze.com/2017/06/16/omeros-co-omer-stake-cut-by-ubs-asset-management-americas-inc-updated-updated.html.

Several equities research analysts have commented on OMER shares. Wedbush reissued an “outperform” rating and issued a $47.00 target price on shares of Omeros Corporation in a report on Tuesday, February 21st. Zacks Investment Research raised Omeros Corporation from a “sell” rating to a “hold” rating in a report on Wednesday, March 15th. WBB Securities reaffirmed a “buy” rating and set a $75.00 price target on shares of Omeros Corporation in a report on Thursday, March 30th. Maxim Group reaffirmed a “buy” rating on shares of Omeros Corporation in a report on Wednesday, March 1st. Finally, Cowen and Company reaffirmed an “outperform” rating on shares of Omeros Corporation in a report on Monday, March 20th. Three investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $32.66.

In other news, VP Michael A. Jacobsen sold 24,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $21.20, for a total transaction of $508,800.00. Following the completion of the transaction, the vice president now directly owns 2,650 shares of the company’s stock, valued at approximately $56,180. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Thomas J. Cable sold 3,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 12th. The stock was sold at an average price of $16.49, for a total transaction of $49,470.00. Following the transaction, the director now directly owns 40,067 shares of the company’s stock, valued at $660,704.83. The disclosure for this sale can be found here. Over the last three months, insiders have sold 39,000 shares of company stock valued at $857,670. Corporate insiders own 13.60% of the company’s stock.

Omeros Corporation Company Profile

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply